SENSEX NIFTY
Jun 12, 2012, 03.54 PM IST | Source: PTI

Venus Remedies receives US patent for antibiotic product

Drug firm Venus Remedies today said it has received patent from the US Patent Office for new antibiotic product which targets drug resistant infections.

Drug firm Venus Remedies today said it has received patent from the US Patent Office for new antibiotic product which targets drug resistant infections.

The product, CSE 1034, has been found to be effective against a wide range of drug resistant infections, including the 'superbugs' the company said in a statement.

Venus Medical Research Centre Vice President Mufti Suhail Sayeed said: "The US patent of CSE 1034 is a landmark development for initiating the process of commercialisation of this novel drug, designed specifically to target growing
bacterial resistance mechanisms".

The innovation achieves greater significance as medical community world over, particularly in India, is looking for ways to deal with the growing problem of antibiotic resistance, the company said.

Emergence of 'superbugs' like carbapenemase resistant Metallobetalactamses has further complicated the scenario, it added.
    
The company said that in view of the urgency, regulatory agencies around the world are currently fast-tracking the approval process of antibiotic drugs.
    
"Even the Infectious Diseases Society of America (IDSA) has recommended to the US Food and Drug Administration (USFDA) to review drugs designed to target antibiotic resistance as 'orphan drugs' to speed up their marketing approval," Sayeed said.
    
On the cost effectiveness of the product VMRC Joint MD Manu Chaudhary said: "Experience with clinical studies on over 1,000 patients have indicated approximately 20 to 30% reduction in cost of therapy compared to conventional therapies being used".
    
Studies conducted in hospitals across India have shown that the novel antibiotic product is suitable for the treatment of a range of infections including hospital acquired (nosocomial) infections, Venus Remedies said.
    
The company is planning to launch this drug in India under the brand name Elores and is planning to have a pre IND meeting with US FDA for fast track approval of this product, it added.
    
"Globally, the antibiotics market generated sales of USD 42 billion in 2009, representing 46% of sales of anti -infective agents and 5 per cent of the global pharmaceutical market," the company claimed.
    
Shares of Venus Remedies were trading at Rs 171.80 per scrip in the afternoon trade on BSE, up 2.78% from the previous close.

Venus Remedies stock price

On December 19, 2014, Venus Remedies closed at Rs 209.90, up Rs 2.10, or 1.01 percent. The 52-week high of the share was Rs 381.75 and the 52-week low was Rs 195.20.


The company's trailing 12-month (TTM) EPS was at Rs 45.35 per share as per the quarter ended September 2014. The stock's price-to-earnings (P/E) ratio was 4.63. The latest book value of the company is Rs 408.51 per share. At current value, the price-to-book value of the company is 0.51.

Set email alert for

ADS BY GOOGLE

video of the day

Rupee weakness modest, see yields at 7.60% in Q1: Deutsche

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.